The development of bronchoscopy and bronchoalveolar lavage (BAL) has led to an increase in their use in intensive care units (ICUs), where their applications for differential diagnosis of pulmonary diseases make them indispensable instruments for intensivists \[[@CR1]\]. Despite their common use, a few studies have raised concerns about potential impacts on bronchoalveolar lavage fluid (BALF) dilution, which affects mainly the quantitative detection of soluble substances. Urea is a diffusible substance that can easily be detected in capillaries and alveolar spaces. The urea concentration in plasma and that in BALF are approximately equal and their ratio (urea plasma/urea BALF) has previously been applied as an index of BALF dilution. Furthermore, it has been shown that the ratio of high-quality lavage is low in clinical settings \[[@CR2], [@CR3]\].

We reviewed all ICU-admitted patients who received BAL from January 2016 to September 2018 in Ren Ji Hospital and analyzed their urea plasma/urea BALF values. Guidelines of the American Thoracic Society were followed during the BAL procedure \[[@CR3]\]. (The procedure is described in Additional file [1](#MOESM1){ref-type="media"}.) Among 223 patients included, the median level of urea plasma/urea BALF was 4.2 (interquartile range of 3.2--8.6). The patients were categorized into groups A (urea plasma/urea BALF \<4.2) and B (urea plasma/urea BALF ≥4.2). The patients in group A were more likely to receive bronchodilators (35.6% versus 15.9%, *P* \<0.001) and a recruitment maneuver (15.5% versus 5.3%, *P* = 0.013) than those in group B. More invasive pulmonary aspergillosis (IPA) patients with BALF galactomannan of more than 0.5 could be detected in group A than in group B (84.6% versus 33.3%, respectively; *P* = 0.019) as well as more bacterial pneumonia patients with the quantitative cultures of BALF of more than 10^4^ CFU/mL (90.6% versus 52.7%, respectively; *P* \<0.001). Primary care physicians performed more BAL than residents did (58.3% versus 31.8%, respectively), especially in group A (Table [1](#Tab1){ref-type="table"}).Table 1Demographics and clinical characteristics of the patientsCharacteristicsAll patientsGroup A\
(urea plasma/urea BALF \<4.2)Group B\
(urea plasma/urea BALF ≥4.2)*P* value*n* = 223*n* = 110*n* = 113Age, years54 (43--67)51 (43--66)56 (43--67)0.945Gender, male103 (46.2)53 (48.2)50 (44.2)0.556BMI, kg/m^2^21.9 (18.5--23.4)22.1 (18.4--23.4)21.8 (18.5--23.4)0.515PaO~2~/FiO~2~210.4 (120.4--271.5)250.9 (206.7--320.5)137.4 (88.6--210.4)\<0.001Pulmonary disease AECOPD68 (30.5)33 (30.0)35 (30.9)0.875 CAP61 (27.4)28 (25.5)35 (30.9)0.36 HAP33 (14.8)17 (15.5)14 (12.4)0.508 VAP16 (7.2)7 (6.4)9 (7.9)0.643 IPA28 (12.6)13 (11.8)15 (13.3)0.743 Others17 (7.5)12 (9.0)5 (4.6)0.068APACHE II score17 (13--23)16 (14--22)17 (13--23)0.799Intubation and mechanical ventilation47 (21.1)21 (19.1)26 (23.0)0.473Lesion location Upper lobe56 (25.1)26 (23.6)30 (26.5)0.616 Middle and lower lobe93 (41.7)51 (46.4)42 (37.2)0.164 Diffusive lesions74 (33.2)33 (30.3)41 (36.3)0.319Sedative and narcotic drugs Midazolam and fentanyl96 (43.0)51 (46.4)45 (39.8)0.324 Propofol and fentanyl89 (39.9)42 (38.2)47 (41.6)0.603 Dexmedetomidine38 (17.1)17 (15.4)21 (18.6)0.534Bronchodilators was given before BAL57 (25.6)39 (35.6)18 (15.9)\<0.001RM before BAL23 (10.3)17 (15.5)6 (5.3)0.013Operator Resident71 (31.8)5 (4.5)66 (58.4)\<0.001 Primary care physician130 (58.3)93 (84.5)37 (32.7)\<0.001 Others22 (9.9)12 (11.0)10 (8.9)0.616Diagnosed with bacterial pneumonia178 (79.8)85 (77.3)93 (82.3)0.348BALF GM \>0.5 in IPA patients16 (57.1)11 (84.6)5 (33.3)0.019Quantitative cultures of BALF \>10^4^ CFU/mL in bacterial pneumonia patients126 (70.8)77 (90.6)49 (52.7)\<0.001Data are expressed as median (Q1--Q3) or number (percentage). *P* values for comparison between urea plasma/urea BALF ≥4.2 and \<4.2 groups.Abbreviations: *AECOPD* acute exacerbation of chronic obstructive pulmonary disease, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *BAL* bronchoalveolar lavage, *BALF* bronchoalveolar lavage fluid, *BMI* body mass index, *CAP* community-acquired pneumonia, *CFU* colony-forming units, *FiO*~*2*~ fractional concentration of inspired oxygen, *GM* galactomannan, *HAP* hospital acquired pneumonia, *IPA* invasive pulmonary aspergillosis, *PaO*~*2*~ partial pressure of arterial oxygen, *RM* recruitment maneuver, *VAP* ventilator-associated pneumonia.

Pulmonary function was associated with the urea plasma/urea BALF ratio. It was found that there was a correlation between urea plasma/urea BALF and partial pressure of arterial oxygen/fractional concentration of inspired oxygen (PaO~2~/FiO~2~) (R^2^ = 0.196, *P* \<0.001). The less oxygen-deficient the patient was, the lower the urea plasma/urea BALF level was (Fig. [1](#Fig1){ref-type="fig"}a,b). Sixty-eight patients with chronic obstructive pulmonary disease (COPD) were enrolled in our study. The forced expiratory volume in the first second (FEV~1~) was suggested as a measure of bronchial obstruction. FEV~1~ of less than 50% of the predicted normal value indicated the presence of severe ventilatory impairment, which led to a lower volume of instilled saline flow into the alveoli. In our study, a correlation was also found between FEV~1~ and urea plasma/urea BALF (R^2^ = 0.299, *P* \<0.001). A lower value of urea plasma/urea BALF was obtained in a group with FEV~1~ of at least 50% of the predicted value than in that with FEV~1~ of less than 50% of the predicted value (*P* \<0.05, Fig. [1](#Fig1){ref-type="fig"}c, d).Fig. 1**a** Correlation between PaO~2~/FiO~2~ and urea plasma/urea BALF. **b** Comparison of urea plasma/urea BALF in different PaO~2~/FiO~2~ groups. **c** Correlation between FEV~1~/FEV~1~ predicted and urea plasma/urea BALF in patients with COPD. **d** Comparison of urea plasma/urea BALF in different FEV~1~/FEV~1~ predicted groups in patients with COPD. \**P* \<0.05 in each group. Abbreviations: *BALF* bronchoalveolar lavage fluid, *COPD* chronic obstructive pulmonary disease, *FEV*~*1*~ forced expiratory volume in the first second, *FiO*~*2*~ fractional concentration of inspired oxygen, *PaO*~*2*~ partial pressure of arterial oxygen.

Providing appropriate training in BAL skills to intensivists while ensuring patient safety is challenging \[[@CR4]\]. Inter-operator variability in the recovery of lavage fluid during a BAL procedure may affect the concentration of soluble substances such as galactomannan and the results of quantitative cultures \[[@CR5]\]. More attention should be paid to patients with hypoxia and impaired pulmonary function. Bronchodilators and a recruitment maneuver may improve BALF dilution during the procedure, and residents in ICUs need more practice.
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Additional file 1:Guidelines of the American Thoracic Society were followed during the bronchoalveolar lavage (BAL) procedure. Selection of the segment for BAL was guided by chest x-ray changes. The right middle lobe or lingual lobe was selected when diffuse infiltrates were present. Five 20-mL aliquots of sterile saline were instilled and aspirated gently in each patient. The total volume of the retrieved liquid should be greater than or equal to 30% of the total volume of the instilled saline. (ZIP 492 kb)
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